Save time and get answers to complex questions with AI chat
Allergan's patent for latisse expired?Abbvie humira patent cliff navigation success?Xenazine current manufacturer 2025?Defense strategy against generic in niche market?Pramlintide acetate price?
See the DrugPatentWatch profile for Alprolix
Alprolix is manufactured by-[(1)] Baxalta US Inc., which is now a subsidiary of Takeda Pharmaceutical Company Limited-[(2)].
Alprolix is a recombinant factor IX Fc fusion protein used for the treatment of hemophilia B-[(1)]. It helps to reduce the frequency of bleeding episodes in individuals with this condition-[(1)].
The drug is designed to extend the half-life of factor IX in the bloodstream, meaning it stays in the body longer than traditional factor IX therapies-[(2)]. This allows for less frequent dosing-[(1)].
Information on Alprolix's patent expiration can be found on DrugPatentWatch.com-[(3)]. Patent expiry dates are crucial for understanding when generic or biosimilar versions of a drug may become available, potentially impacting pricing and market competition-[(3)].
Other treatments for hemophilia B include other recombinant factor IX products and plasma-derived factor IX concentrates. The development of extended half-life factor products has intensified competition in the hemophilia treatment market-[(2)].
Other Questions About Alprolix :